All News
The RheumNow Week in Review – 6 May 2016
Watch Dr. Cush discuss the highlights from this week on RheumNow.com.
Read Article
Biosimilar Switching Shows Favorable Interchangeability
Interchangeability is a major issue that will determine the success of biosimilars.
Read Article
Low Adherence to Biologics in Psoriasis Patients
Doshi and colleagues have conducted a retrospective claims analysis (2009 through 2012) of psoriasis patients on Medicare to examine the use and adherence to those initiating treatment with either infliximab, etanercept, adalimumab, or ustekinumab.
Read Article
Can Rituximab Change the Course of Interstitial Lung Disease?
Like other extraarticular manifestations, rheumatoid (RA) or connective tissue disease (CTD) related interstitial lung disease (ILD) is difficult to identify early and equally challenging to treat.
Read Article
Vaccine Success is Limited in Rheumatoid Arthritis
Numerous guidelines (ACR, ACIP/CDC, ATS, NICE) all call for timely vaccinations in patients with rheumatoid arthritis (RA) and those receiving immunosuppressives or biologics.
Read Article
Posterior Reversible Encephalopathy in Lupus
Posterior reversible encephalopathy syndrome (PRES) is a rare neurological disorder with many associations or causative factors that rarely includes autoimmune disorders and lupus.
Read Article
Biosimilar Reports - April 2016
Major advances in biosimilars have occurred in the last three months, beginning with the FDA Arthritis Advisory Committee voting 21-3 to approve Celltrion’s Inflectra (CT-P13) and ending with the recent approval of Inflectra (generically referred to as infliximab dyyb).
Read Article
Lupus Patients Genomically Stratified to Explain Treatment Responses
Systemic lupus is a clinically heterogeneous disorder, unified by requisite clinical features and exuberant humoral response to unknown triggers. While the diagnosis is easy, the disease course and management can be complicated and challenging.
Read Article
Population-Based TB Risk and Prevention with RA and Biologics
In a retrospective cohort comparison study, 42,180 rheumatoid arthritis (RA) patients were compared 1:4 with 168,000 normal controls to examine the incidence of new tuberculosis in Taiwan. The RA population included those receiving csDMARDs (36,162), etanercept (3,577), adalimumab (1,67
Read Article
A Rocky Start for Biosimilar Inflectra?
This week, when the FDA approved the biosimilar drug Inflectra as an alternative to infliximab (Remicade), it was only the second biosimilar to be granted approval in the United States, and was the fi
Read Article
RheumNow Week in Review - 8 April 2016
Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:
Read Article
Altering the Microbiome May Benefit Lupus Patients
Lopez and colleagues from Spain have studied the gut microbiome of l
Read Article
Tofacitinib Efficacy Revealed in OPAL Study
Pfizer has issued a press release of its preliminary results from the OPAL study that examined the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adults active psoriatic arthritis (PsA).
Read Article
FDA Biosimilar Approval of Inflectra Viewed as a Milestone Advance
On February 9th, the Food and Drug Administration (FDA) Arthritis Advisory Committee voted 21-3 in favor of approving the infliximab biosimilar, CT-P13/Inflectra, for use in all of infliximab's indications.
Read Article
Baricitinib Benefits Refractory RA
The small molecule oral JAK inhibitor baricitinib was effective for patients with highly refractory rheumatoid arthritis, a phase III study found.
Read Article
First Head-to-Head TNF Trial Ends in a Draw
Comparative efficacy trials may be the best way to make informed treatment choices in a sea of treatment options for rheumatoid arthritis (RA). Recent years have seen impressive head-to-head (H2H) clinical trials for RA, including AMPLE (abatacept vs.
Read Article
The Week in Review 18 March 2016
See the highlights from the past week that appeared on RheumNow.com, and watch Dr. Jack Cush as he reviews each of them.
Read Article
January/February 2016 Top Social Media News
In February 2016, RheumNow published 82 tweets about impactful news, research and teaching points that impact the rheumatology community. These feeds had a reach (impressions) of 80,800 with, 76 mentions, and over 2700 visits to learn on RheumNow.com.
Read Article
TNF Inhibitors Increase Perioperative Infection Risk
The use of tumour necrosis factor α inhibitors (TNFis) at the time of major surgery has been a challenge for surgeons, rheumatologists and those wishing to develop evidence-based guidelines for this clinical scenario.
Read Article
IL-6 Inhibition Makes News
Several new interleukin-6 inhibitors made headlines this week. While none of the new IL-6 inhibitors are soon to be approved and available, these studies may redefine the role of other non-TNF biologics in the future.
Read Article
